BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
0.5284 USD   +1.60%
08/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/27BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/27Brooklyn ImmunoTherapeutics, Inc. Announces the resignation of Kevin D’Amour as Chief Scientific Officer
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from S&P Global BMI Index

06/20/2022 | 12:00am EDT

Brooklyn ImmunoTherapeutics, Inc.(NasdaqGM:BTX) dropped from S&P Global BMI Index


© S&P Capital IQ 2022
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
08/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/27BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/27Brooklyn ImmunoTherapeutics, Inc. Announces the resignation of Kevin D’Amour as Ch..
CI
07/26Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Nec..
AQ
07/26Brooklyn ImmunoTherapeutics, Inc. Announces Results of Phase 2 Study of IRX-2 in Head a..
CI
07/01BROOKLYN IMMUNOTHERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued ..
AQ
07/01BROOKLYN IMMUNOTHERAPEUTICS : Quarterly Report (Form 10-Q)
PU
07/01Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended ..
CI
07/01BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Co..
AQ
07/01BROOKLYN IMMUNOTHERAPEUTICS, INC. - 10-K/A - Management's Discussion and Analysis of Fi..
AQ
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -27,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,00x
Yield 2022 -
Capitalization 30,4 M 30,4 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 10
Free-Float 73,4%
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,53 $
Average target price 3,00 $
Spread / Average Target 468%
EPS Revisions
Managers and Directors
Matthew Angel President, Chief Executive Officer & Director
Andrew C. Jackson Chief Financial Officer
Charles Reed Cherington Director
Kevin A. D'Amour Chief Scientific Officer
Roger Sidhu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.-87.33%30
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235